In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.

Tamoxifen treatment for premenopausal women with breast cancer is independently associated with an increased risk of endometrial cancer and other uterine diseases, according to findings from a large ...

Tamoxifen use in the treatment of breast cancer was associated with greater risks for endometrial cancer, hyperplasia and polyps, as well as other uterine cancers among premenopausal women in Korea, ...

It is known that tamoxifen has an estrogenic proliferating effect on the endometrial lining of the uterus including the development of endometrial polyps, hyperplasia, and fibroid growth. These ...

Successful Treatment of Metastatic Renal Cell Carcinoma With a Nonmyeloablative Allogeneic Peripheral-Blood Progenitor-Cell Transplant: Evidence for a Graft-Versus-Tumor Effect PURPOSE: Tamoxifen is ...

Several studies report an increase of endometrial cancer (EC) risk in breast cancer patients after long-term tamoxifen treatment (Fornander et al, 1989; Fisher et al, 1994, Cecchini et al, 1998); such ...

UCSF researchers have identified a new “feed-forward” pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth. The ...

A study led by Loyola Medicine researchers may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer. The multi-center study was published in ...

A new study done in mice suggests that taking raloxifene after 5 years of tamoxifen therapy may not further prevent the growth of breast cancers. What's more, raloxifene may stimulate the growth of ...

Treatment cuts risk of death and recurrence, but some women still go without. July 29, 2011— -- For women diagnosed with hormone-sensitive breast cancer-- more than 150,000 in the U.S. each year- ...